Business Description
Savara Inc
NAICS : 325412
SIC : 2834
ISIN : US8051111016
Total Employee Number:
70Description
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.69 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.21 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -30.6 | |||||
3-Year EPS without NRI Growth Rate | -28.4 | |||||
3-Year FCF Growth Rate | -26.2 | |||||
3-Year Book Growth Rate | 1.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 460.89 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.43 | |||||
9-Day RSI | 41.82 | |||||
14-Day RSI | 43.39 | |||||
3-1 Month Momentum % | 8.31 | |||||
6-1 Month Momentum % | -6.55 | |||||
12-1 Month Momentum % | 70.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.13 | |||||
Quick Ratio | 10.13 | |||||
Cash Ratio | 9.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 | |||||
Shareholder Yield % | 0.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -94.42 | |||||
ROA % | -71.67 | |||||
ROIC % | -862.81 | |||||
3-Year ROIIC % | -1543.45 | |||||
ROC (Joel Greenblatt) % | -66407.44 | |||||
ROCE % | -80.39 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.65 | |||||
Price-to-Tangible-Book | 8.32 | |||||
EV-to-EBIT | -6.7 | |||||
EV-to-Forward-EBIT | -9.73 | |||||
EV-to-EBITDA | -6.71 | |||||
EV-to-Forward-Revenue | 8.7 | |||||
EV-to-FCF | -8.64 | |||||
| Price-to-Net-Current-Asset-Value | 8.47 | |||||
| Price-to-Net-Cash | 8.8 | |||||
Earnings Yield (Greenblatt) % | -14.93 | |||||
FCF Yield % | -10.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Savara Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.499 | ||
| Beta | 1.1102 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 0.77 | ||
| Volatility % | 51.82 | ||
| 14-Day RSI | 43.39 | ||
| 14-Day ATR (€) | 0.178281 | ||
| 20-Day SMA (€) | 4.72005 | ||
| 12-1 Month Momentum % | 70.98 | ||
| 52-Week Range (€) | 2.78 - 5.85 | ||
| Shares Outstanding (Mil) | 205.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Savara Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Savara Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 71 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 4.93 (-0.30%) | ||
| General meeting for 2026 | 2026-06-04 15:00 | 4.47 (+1.04%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:05 | 4.48 (+3.70%) | ||
| H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference | 2026-05-19 10:00 | 4.21 (-0.05%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.33 (-0.37%) | ||
| Annual report for 2025 | 2026-03-13 | 4.60 (-2.95%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 4.60 (-2.95%) | ||
| The Citizens Life Science Conference | 2026-03-11 10:10 | 4.80 (+3.00%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-14 20:15 | 5.00 (+2.88%) |
Show
Entries
Savara Inc Frequently Asked Questions
What is Savara Inc(STU:YB4P)'s stock price today?
The current price of STU:YB4P is €4.58. The 52 week high of STU:YB4P is €5.85 and 52 week low is €2.78.
When is next earnings date of Savara Inc(STU:YB4P)?
The next earnings date of Savara Inc(STU:YB4P) is 2026-11-12 Est..
Does Savara Inc(STU:YB4P) pay dividends? If so, how much?
Savara Inc(STU:YB4P) does not pay dividend.
Press Release
Articles on Savara Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers